Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals has allotted 26,000 equity shares under ESOS on 19 June 2026. With this allotment, the paid up equity share capital has increased to 18,96,80,147 equity shares of Rs. 10/- each aggregating to Rs. 1,89,68,01,470/-.

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra' (semaglutide injection) across India. The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses). The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing. As the first Indian company to exclusively distribute and commercialise Poviztra', a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

Emcure Pharmaceuticals announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India. Under the agreement, which will be effective 01 April 2026, Emcure will distribute Roche's established and globally recognised brands in the nephrology and transplant segment in India. The agreement includes the following brands: CellCept' ' A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995. Mircera' and Neorecormon' ' Proven therapies for anemia in chronic kidney disease, including Mircera's long-acting ESA with dosing once every 2'4 weeks. Commenting on the agreement, Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals, said, 'This partnership with Roche is a natural extension of Emcure's commitment to improving outcomes in anemia and renal care. Roche's globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering op mal care to patients across India.'  Powered by Capital Market - Live

Net profit of Emcure Pharmaceuticals rose 49.97% to Rs 230.54 crore in the quarter ended December 2025 as against Rs 153.72 crore during the previous quarter ended December 2024. Sales rose 20.42% to Rs 2363.48 crore in the quarter ended December 2025 as against Rs 1962.63 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2363.481962.63 20 OPM %20.8518.07 - PBDT456.62326.73 40 PBT351.94229.92 53 NP230.54153.72 50 Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2026.Powered by Capital Market - Live

The domestic equity indices traded with minor gains in the early trade. Investors are keeping a close watch on rupee movement, FII activity, IPO activity and other global developments. The Nifty traded above the 26,200 level. Realty, media and consumer durables shares advanced while IT, FMCG and auto shares declined. At 09:25 IST, the barometer index, the S&P BSE Sensex advanced 78.58 points or 0.09% to 85,603.42. The Nifty 50 index jumped 35.30 points or 0.13% to 26,209.50. In the broader market, the S&P BSE Mid-Cap index rose 0.07% and the S&P BSE Small-Cap index rose 0.38%. The market breadth was strong. On the BSE, 2,040 shares rose and 856 shares fell. A total of 158 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 1,794.80 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 3,812.37 crore in the Indian equity market on 23 December 2025, provisional data showed. The stock market will be closed tomorrow, 25 December 2025, on account of Christmas. Numbers to Track: The yield on India's 10-year benchmark federal paper shed 0.48% to 6.637 compared with previous session close of 6.637. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 89.5750 compared with its close of 89.6300 during the previous trading session. MCX Gold futures for 5 February 2026 settlement advanced 0.27% to Rs 138,253. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.01% to 97.91. The United States 10-year bond yield declined 0.31% to 4.156. In the commodities market, Brent crude for February 2025 settlement added 5 cents or 0.08% to $62.43 a barrel. Stocks in Spotlight: GAIL (India) rose 0.76%. The company has signed memorandum of understanding (MoU) with Government of Chhattisgarh for development of a greenfield gas-based fertilizer project in Chhattisgarh. Vikran Engineering surged 13.20% after the company received a Rs 2035 crore order from Onix Renewables for EPC works for solar plant development. Emcure Pharmaceuticals advanced 1.60% after the company has received establishment inspection report (EIR). The US FDA has classified the inspection of the facility as no action indicated (NAI). Inspection was conducted from 6 October to 10 October 2025. Global markets: Asian market traded advanced on Wednesday, with several indexes set to close early in lieu of the Christmas Eve holiday. Media reports from Japan said that the country was set to issue about 29.6 trillion yen (about $190 billion) in new government bonds to fund its fiscal 2026 budget. The South Korean won strengthened against the greenback after media reports stated that South Korea's national pension fund was carrying out strategic foreign exchange hedging activities. Spot gold prices hit another record Wednesday, crossing $4,500 per ounce for the first time, driven by a weaker dollar, geopolitical tensions and U.S. Federal Reserve rate-cut expectations. Gold has notched a series of all-time highs this year, soaring over 70% year to date. Overnight in the U.S., stocks rose for a fourth straight session as artificial intelligence names continued to outperform during a holiday-shortened week. The S&P 500 added 0.46%, closing at a record level of 6,909.79. The broad market index is now just below its intraday all-time high of 6,920.34. The Nasdaq Composite climbed 0.57% to end at 23,561.84. Gains in tech giants such as Nvidia and Broadcom lifted the index. The Dow Jones Industrial Average rose 79.73 points, or 0.16%, and settled at 48,442.41.Powered by Capital Market - Live

Net profit of Emcure Pharmaceuticals rose 25.13% to Rs 243.46 crore in the quarter ended September 2025 as against Rs 194.57 crore during the previous quarter ended September 2024. Sales rose 13.38% to Rs 2269.82 crore in the quarter ended September 2025 as against Rs 2001.98 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2269.822001.98 13 OPM %20.9519.03 - PBDT446.06370.31 20 PBT341.42273.41 25 NP243.46194.57 25 Powered by Capital Market - Live

Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra', semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India. Wegovy' (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy' experienced weight loss of over 20%.2 Poviztra' is a second brand of Wegovy'. This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz tra', semaglutide injection 2.4 mg, in India. Powered by Capital Market - Live

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live